Aliases & Classifications for Retinitis

MalaCards integrated aliases for Retinitis:

Name: Retinitis 12 54 15 71

Classifications:



External Ids:

Disease Ontology 12 DOID:3612
MeSH 43 D012173
NCIt 49 C115993
SNOMED-CT 67 399463004
ICD10 32 H30.9
UMLS 71 C0035333

Summaries for Retinitis

MalaCards based summary : Retinitis is related to retinitis pigmentosa 43 and retinitis pigmentosa 35. An important gene associated with Retinitis is RPGR (Retinitis Pigmentosa GTPase Regulator), and among its related pathways/superpathways are Metabolism of fat-soluble vitamins and Visual Cycle in Retinal Rods. The drugs Sodium citrate and Valganciclovir have been mentioned in the context of this disorder. Affiliated tissues include retina, eye and testes, and related phenotypes are Decreased HPV16-GFP infection and nervous system

Related Diseases for Retinitis

Diseases related to Retinitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2833)
# Related Disease Score Top Affiliating Genes
1 retinitis pigmentosa 43 34.5 RPGR PDE6A
2 retinitis pigmentosa 35 34.4 SEMA4A RPGR
3 retinitis pigmentosa 25 34.3 RPGR EYS
4 retinitis pigmentosa 73 34.3 EYS CERKL
5 retinitis pigmentosa 55 34.2 RPGR FAM161A
6 late-onset retinal degeneration 34.2 RPGR RPE65 RHO PRPH2 EYS
7 retinitis pigmentosa 37 34.1 RPGR RP9
8 retinal perforation 34.1 RPE65 RLBP1
9 retinitis pigmentosa 26 34.1 RPGR CERKL
10 retinitis pigmentosa 20 34.1 RPGR RPE65 RP9
11 retinitis pigmentosa 19 34.0 RPGR RP9 PRPH2
12 retinitis pigmentosa 62 34.0 TOPORS FAM161A
13 retinitis pigmentosa 12 34.0 RPGR RP9
14 hereditary retinal dystrophy 34.0 RPE65 RHO PRPH2 EYS
15 retinitis pigmentosa 14 33.9 RPGR RP9 CERKL
16 retinitis pigmentosa 6 33.9 RPGR RP9
17 retinitis pigmentosa 28 33.9 RPGR FAM161A
18 retinitis pigmentosa 29 33.9 PDE6A FAM161A CERKL
19 retinitis pigmentosa 9 33.8 RP9 IMPDH1
20 retinitis pigmentosa 10 33.8 RPGR RP9 IMPDH1
21 retinitis pigmentosa 54 33.8 RP9 FAM161A
22 retinitis pigmentosa 17 33.8 RPGR RP9 IMPDH1
23 retinitis pigmentosa 1 33.7 RPGR RP1 RHO PRPH2 PDE6A IMPDH1
24 retinitis pigmentosa 3 33.7 RPGRIP1 RPGR RP9 RP2
25 retinitis pigmentosa 7 33.6 SNRNP200 RPGR RP9 PRPH2 PDE6A
26 retinitis pigmentosa 4 33.6 SNRNP200 RPGR RP9 RP2 RHO
27 retinitis pigmentosa 34 33.6 RPGRIP1 RPGR RP9
28 usher syndrome, type i 33.5 RPGR RPE65 RHO IMPDH1
29 retinitis pigmentosa 33 33.4 SNRNP200 RP9 PRPF3
30 retinal ciliopathy 33.3 RPGRIP1 RPGR RP1
31 vitreoretinochoroidopathy 33.3 RPE65 PRPH2
32 macular dystrophy, dominant cystoid 33.3 RPE65 PRPH2 PDE6A
33 retinoschisis 1, x-linked, juvenile 33.3 RPGR RPE65 RHO
34 retinitis pigmentosa 13 33.2 SNRNP200 RPGR RP9 PRPF3
35 enhanced s-cone syndrome 33.2 RPGR RPE65 RHO
36 usher syndrome 33.2 RPGR RPE65 RHO PRPH2 PDE6A EYS
37 peripheral retinal degeneration 33.1 RPGR RLBP1 RHO PRPH2 IMPDH1 CERKL
38 bestrophinopathy, autosomal recessive 33.0 RPE65 RLBP1 PRPH2
39 leber congenital amaurosis 3 33.0 RPGRIP1 RPE65 IMPDH1
40 macular degeneration, age-related, 1 33.0 RPGR RPE65 RLBP1 RHO PRPH2 FLVCR1
41 choroideremia 32.9 RPGR RPE65 RHO
42 pattern dystrophy 32.9 RP2 RHO PRPH2
43 fundus albipunctatus 32.9 RPGR RPE65 RLBP1 RHO PRPH2 EYS
44 leber congenital amaurosis 4 32.8 RPGRIP1 RPE65 PRPH2 PDE6A IMPDH1
45 cone-rod dystrophy 6 32.8 RPGRIP1 RPGR RPE65 PRPH2 PDE6A CERKL
46 vitelliform macular dystrophy 32.8 RPGR RPE65 PRPH2
47 retinitis pigmentosa 31 32.8 TOPORS RPGR RP9 PRPF3 FAM161A
48 newfoundland rod-cone dystrophy 32.8 RLBP1 PRPH2
49 cone dystrophy 32.8 RPGR RPE65 RLBP1 RHO PRPH2 EYS
50 leber congenital amaurosis 8 32.7 RPE65 IMPDH1

Graphical network of the top 20 diseases related to Retinitis:



Diseases related to Retinitis

Symptoms & Phenotypes for Retinitis

GenomeRNAi Phenotypes related to Retinitis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased HPV16-GFP infection GR00350-A 8.92 FLVCR1 IMPDH1 RP2 RPE65

MGI Mouse Phenotypes related to Retinitis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 9.93 FAM161A PDE6A PRPH2 RHO RLBP1 RP1
2 pigmentation MP:0001186 9.5 PRPF3 PRPH2 RHO RLBP1 RPE65 RPGR
3 vision/eye MP:0005391 9.47 CERKL FAM161A IMPDH1 PDE6A PRPF3 PRPH2

Drugs & Therapeutics for Retinitis

Drugs for Retinitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 229)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sodium citrate Approved, Investigational Phase 4 68-04-2
2
Valganciclovir Approved, Investigational Phase 4 175865-60-8 64147
3
Ranibizumab Approved Phase 4 347396-82-1 459903
4
Pancrelipase Approved, Investigational Phase 4 53608-75-6
5
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
6 Citrate Phase 4
7 Sildenafil Citrate Phase 4 171599-83-0
8 Antiviral Agents Phase 4
9 Anti-Infective Agents Phase 4
10 Antibodies Phase 4
11 Immunoglobulins Phase 4
12 Phosphodiesterase Inhibitors Phase 4
13 Phosphodiesterase 5 Inhibitors Phase 4
14 Vasodilator Agents Phase 4
15 Angiogenesis Inhibitors Phase 4
16 pancreatin Phase 4
17 Vardenafil Dihydrochloride Phase 4
18
Eplerenone Approved Phase 2, Phase 3 107724-20-9 150310 443872
19
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
20
Tocopherol Approved, Investigational Phase 3 1406-66-2, 54-28-4 14986
21
Acyclovir Approved Phase 3 59277-89-3 2022
22
Ganciclovir Approved, Investigational Phase 2, Phase 3 82410-32-0 3454
23
Lutein Approved, Investigational, Nutraceutical Phase 3 127-40-2 6433159
24
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
25
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
26
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
27 Molgramostim Investigational Phase 3 99283-10-0
28 Tocotrienol Investigational Phase 3 6829-55-6
29 Hormones Phase 2, Phase 3
30 Hormone Antagonists Phase 2, Phase 3
31 Mineralocorticoids Phase 2, Phase 3
32 Mineralocorticoid Receptor Antagonists Phase 2, Phase 3
33 diuretics Phase 2, Phase 3
34 Diuretics, Potassium Sparing Phase 2, Phase 3
35 Immunologic Factors Phase 3
36 Antibodies, Monoclonal Phase 2, Phase 3
37 Protective Agents Phase 3
38 Trace Elements Phase 3
39 Vitamins Phase 3
40 Nutrients Phase 3
41 Micronutrients Phase 3
42 Calciferol Phase 3
43 Antioxidants Phase 3
44 Tocotrienols Phase 3
45 Tocopherols Phase 3
46 Ganciclovir triphosphate Phase 2, Phase 3
47 Lecithin Phase 2, Phase 3
48 Retinol palmitate Phase 2, Phase 3
49 retinol Phase 2, Phase 3
50 Antihypertensive Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 281)
# Name Status NCT ID Phase Drugs
1 A Prospective, Randomized, 3-arm Parallel Trial to Evaluate the Safety and Clinical Effectiveness of 2 Lower Dose Combined PDE5i's vs. Single Maximal Dose PDE5i Treatment Unknown status NCT00498680 Phase 4 Sildenafil, Vardenafil;Sildenafil;Vardenafil;Sildenafil & Vardenafil
2 Role of Capsular Tension Ring in Anterior Capsular Contraction in Retinitis Pigmentosa Patients Completed NCT00717080 Phase 4
3 A Multicenter Study of Oral Versus Intravenous Hydration in AIDS Patients With CMV Retinitis Treated With Foscavir (Foscarnet Sodium) Completed NCT00002125 Phase 4 Foscarnet sodium
4 Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT) Completed NCT00000894 Phase 4 Cidofovir;Probenecid;Ganciclovir
5 Pharmacokinetics of Cidofovir During Continuous Venovenous Hemofiltration Completed NCT01866397 Phase 4
6 Use of Cidofovir Injection in the Treatment of Recurrent Respiratory Papillomatosis." Completed NCT00205374 Phase 4 Cidofovir;Placebo
7 Open, Randomised Study Comparing Preemptive Therapy With Intravenous Ganciclovir With and Without Additional Oral Ganciclovir for CMV Prophylaxis in Immunosuppressed Renal Transplant Patients Receiving Monitoring of CMV Viral Load Completed NCT00373165 Phase 4 Ganciclovir
8 Correlation of Functional and Structural Outcomes With Serum Antibody Profiles in Patients With Neovascular Age-related Macular Degeneration Treated With Ranibizumab and Healthy Subjects: A Prospective, Controlled Monocenter Trial Completed NCT02843490 Phase 4 Ranibizumab
9 Pharmacokinetics of Valganciclovir in Kidney and Kidney/Pancreas Transplant Recipients Completed NCT00034385 Phase 4 Valganciclovir
10 An Integrated Approach With Vardenafil Orodispersible and Cognitive-behavioral Sex Therapy for the Treatment of Erectile Dysfunction (STEDOV) Completed NCT02450188 Phase 4 Vardenafil
11 Open-Label Safety Study of Valganciclovir in Patients With CMV Retinitis and AIDS Who Have Complications Due to IV Treatment Unknown status NCT00017784 Phase 3 Valganciclovir
12 A Randomized, Double-masked, Placebo Controlled Study of the Beneficial Effects of Eplerenone on Central Serous Chorioretinopathy Unknown status NCT02215330 Phase 2, Phase 3 Eplerenone;Maltodextrin
13 A Randomized, Controlled Study of Intravenous Ganciclovir Therapy for Peripheral Cytomegalovirus Retinitis in Patients With AIDS Completed NCT00000688 Phase 3 Ganciclovir
14 Foscarnet-Ganciclovir CMV Retinitis Trial Completed NCT00000136 Phase 3 Foscarnet;Ganciclovir
15 Phase III Ganciclovir +/- rGM-CSF for AIDS-Related CMV Retinitis Completed NCT00002070 Phase 3 Sargramostim;Ganciclovir
16 A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes Completed NCT00002377 Phase 3 Valganciclovir;Ganciclovir
17 Cytomegalovirus Retinitis Retreatment Trial Completed NCT00000134 Phase 3 Ganciclovir;Foscarnet
18 A Treatment Protocol for the Use of Intravenous Ganciclovir in AIDS Patients With Immediately Sight-Threatening CMV Retinitis Completed NCT00000698 Phase 3 Ganciclovir
19 Studies of the Ocular Complications of AIDS (SOCA)--HPMPC Peripheral CMV Retinitis Trial (HPCRT) Completed NCT00000142 Phase 2, Phase 3 Cidofovir
20 Monoclonal Antibody CMV Retinitis Trial (MACRT) Completed NCT00000135 Phase 2, Phase 3 MSL-109
21 Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT) Completed NCT00000143 Phase 3 Cidofovir intravenous
22 Ganciclovir Implant Study for Cytomegalovirus Retinitis Completed NCT00000118 Phase 3
23 Randomized Clinical Trial for Retinitis Pigmentosa Completed NCT00346333 Phase 3 Lutein
24 Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa Completed NCT00000114 Phase 3 Vitamin E;Vitamin A
25 Randomized Trial for Retinitis Pigmentosa Completed NCT00000116 Phase 3 Vitamin A;Nutritional Supplement
26 Management of Retinitis Pigmentosa by Wharton's Jelly Derived Mesenchymal Stem Cells: Preliminary Clinical Results Completed NCT04224207 Phase 3
27 A Phase III, Prospective, Randomized, Double-Blind Trial of Valganciclovir Pre-Emptive Therapy for Cytomegalovirus (CMV) Viremia as Detected by Plasma CMV DNA PCR Assay Completed NCT00006145 Phase 3 Valganciclovir
28 An Investigator Initiated Prospective Randomized, Controlled Pilot Study in Order to Evaluate the Place of Valganciclovir in Prevention of Cytomegalovirus Reactivation Following Allogeneic Stem Cell Transplantation Completed NCT00330018 Phase 3 Valganciclovir;Acyclovir
29 A Dose Escalation (Phase 1), and Dose Expansion (Phase 2/3) Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using an Adeno-Associated Viral Vector (AAV8) Encoding Retinitis Pigmentosa GTPase Regulator (RPGR) Recruiting NCT03116113 Phase 2, Phase 3
30 The Effect of Oral Administration of 9-cis β Carotene Rich Powder of the Alga Dunaliella Bardawil on Visual Functions in Patients With Retinitis Pigmentosa Recruiting NCT01680510 Phase 2, Phase 3
31 Systemic and Topical Antivirals for Control of Cytomegalovirus Anterior Uveitis: Treatment Recruiting NCT03586284 Phase 2, Phase 3 Valganciclovir Hydrochloride;Ganciclovir Sodium;Placebo Oral Tablet;Topical placebo
32 A Safety and Efficacy Study in Subjects With Leber Congenital Amaurosis (LCA) Using Adeno-Associated Viral Vector to Deliver the Gene for Human RPE65 to the Retinal Pigment Epithelium (RPE) [AAV2-hRPE65v2-301] Active, not recruiting NCT00999609 Phase 3
33 Safety and Efficacy of Zuretinol Acetate Oral Solution in Subjects With Inherited Retinal Disease Caused by Mutations in Retinal Pigment Epithelium Protein 65 or Lecithin:Retinol Acyltransferase Not yet recruiting NCT04311112 Phase 2, Phase 3 Placebos;ZA Low dose;ZA high dose
34 Phase III Clinical Study of UF-021 for Retinitis Pigmentosa - Evaluation for a Comparative Double Masked Placebo Controlled Study Period and a Continuous Administration Period Terminated NCT01786395 Phase 3 UF-021;Placebo
35 Argus® II Retinal Stimulation System Feasibility Protocol Unknown status NCT00407602 Phase 2
36 An Open Labeled Clinical Study to Evaluate the Safety and Efficacy OF Autologous Bone Marrow Derived Mono Nuclear Stem Cell (BMMNCs) in Retinitis Pigmentosa. It is Self Funded (Patients' Own Funding) Clinical Trial Unknown status NCT01914913 Phase 1, Phase 2
37 Prospective Non-randomised Exploratory Study to Assess the Safety and Efficacy of Aflibercept (Eylea) in Cystoid Macular Oedema (CMO) Associated With Retinitis Pigmentosa (RP) Unknown status NCT02661711 Phase 2 Aflibercept
38 Dexamethasone in Retinitis Pigmentosa Cystoid Macular Edema Unknown status NCT02804360 Phase 2
39 A Phase II, Randomized, Placebo-Controlled Study to Determine the Effects of Viracept on the Clinical Outcome of Cytomegalovirus (CMV) Retinitis in AIDS Patients Who Are Receiving Standard Induction and Maintenance Therapy for This Infection Completed NCT00002169 Phase 2 Nelfinavir mesylate
40 Nerve Growth Factor Eye Drops as a Novel Treatment for Vision Loss in Patients With Retinitis Pigmentosa: From Preclinical to Clinical Phase II Trial Completed NCT02609165 Phase 2 rhNGF 180 µg/ml eye drops solution;vehicle eye drops
41 Efficacy and Safety of Oral Valproic Acid for Retinitis Pigmentosa Completed NCT01399515 Phase 2 Valproic Acid
42 A Phase II/III Trial of Human Anti-CMV Monoclonal Antibody MSL 109 (MACRT) Completed NCT00000836 Phase 2 Sevirumab
43 A Phase II/III Study of the Safety and Efficacy of 1-(S)-(3-Hydroxy-2-Phosphonylmethoxypropyl)Cytosine Dihydrate (Cidofovir; HPMPC) for the Treatment of Peripheral Cytomegalovirus Retinitis in Patients With AIDS Completed NCT00002437 Phase 2 Cidofovir;Probenecid
44 An Exploratory Study to Evaluate the Safety of Brimonidine Intravitreal Implant in Patients With Retinitis Pigmentosa Completed NCT00661479 Phase 1, Phase 2 400 µg Brimonidine Tartrate Implant;200 µg Brimonidine Tartrate Implant;100 µg Brimonidine Tartrate Implant
45 CMV Retinitis Retreatment Trial Completed NCT00000766 Phase 2 Foscarnet sodium;Ganciclovir
46 A Phase II Multiple Site, Randomized, Placebo-Controlled Trial of Oral Valproic Acid for Autosomal Dominant Retinitis Pigmentosa Completed NCT01233609 Phase 2 Valproic Acid;Placebo
47 An Open-Label Study of the Safety and Efficacy of Intravitreal ISIS 2922 in Acquired Immune Deficiency Syndrome (AIDS) Patients With Cytomegalovirus Retinitis (NOTE: Restricted to Patients Who Rollover From Another Controlled ISIS 2922 Trial) Completed NCT00002356 Phase 2 Fomivirsen sodium
48 A Randomized Comparison of Intravitreal ISIS 2922 Plus Ganciclovir Versus Ganciclovir as Treatment for Patients With Cytomegalovirus Retinitis ( CMVR ) Completed NCT00002156 Phase 2 Fomivirsen sodium;Ganciclovir
49 Phase II Randomized Study of Cidofovir for Peripheral Cytomegalovirus Retinitis Completed NCT00004794 Phase 2 cidofovir
50 A Prospective, Multicenter, Open-Label, Single-Arm Study of the Safety and Tolerability of a Single, Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects With Retinitis Pigmentosa (RP) Completed NCT02320812 Phase 1, Phase 2

Search NIH Clinical Center for Retinitis

Genetic Tests for Retinitis

Anatomical Context for Retinitis

MalaCards organs/tissues related to Retinitis:

40
Retina, Eye, Testes, Bone, T Cells, Bone Marrow, Kidney

Publications for Retinitis

Articles related to Retinitis:

(show top 50) (show all 11986)
# Title Authors PMID Year
1
Effects of prolonged dark adaptation in patients with retinitis pigmentosa of Bothnia type: an electrophysiological study. 61 54
17922155 2008
2
The retinal ciliopathies. 54 61
17896309 2007
3
Homozygous deletion related to Alu repeats in RLBP1 causes retinitis punctata albescens. 54 61
17065479 2006
4
Common and divergent roles for members of the mouse DCX superfamily. 61 54
16628014 2006
5
Towards mutation-independent silencing of genes involved in retinal degeneration by RNA interference. 54 61
15877050 2005
6
Novel mutation in RLBP1 gene in a Japanese patient with retinitis punctata albescens. 61 54
15953459 2005
7
A novel compound heterozygous mutation in the cellular retinaldehyde-binding protein gene (RLBP1) in a patient with retinitis punctata albescens. 61 54
15234312 2004
8
Novel mutations in the cellular retinaldehyde-binding protein gene (RLBP1) associated with retinitis punctata albescens: evidence of interfamilial genetic heterogeneity and fundus changes in heterozygotes. 54 61
14718298 2004
9
Antisense oligonucleotides for cancer therapy-an overview. 54 61
12867066 2003
10
Identification and characterisation of the retinitis pigmentosa 1-like1 gene (RP1L1): a novel candidate for retinal degenerations. 61 54
12634863 2003
11
Retinitis pigmentosa-associated rhodopsin mutations in three membrane-located cysteine residues present three different biochemical phenotypes. 61 54
12359230 2002
12
Progressive photoreceptor degeneration, outer segment dysplasia, and rhodopsin mislocalization in mice with targeted disruption of the retinitis pigmentosa-1 (Rp1) gene. 54 61
11960024 2002
13
Clinical features and mutations in patients with dominant retinitis pigmentosa-1 (RP1). 54 61
11527933 2001
14
Antisense therapy in oncology: new hope for an old idea? 61 54
11513935 2001
15
Fundus albipunctatus and retinitis punctata albescens in a pedigree with an R150Q mutation in RLBP1. 54 61
11453974 2001
16
Evaluation of RLBP1 in 50 autosomal recessive retinitis pigmentosa and 4 retinitis punctata albescens Spanish families. 54 61
11262646 2001
17
Full-length human L1 insertions retain the capacity for high frequency retrotransposition in cultured cells. 61 54
10401005 1999
18
Mutations in the gene encoding 11-cis retinol dehydrogenase cause delayed dark adaptation and fundus albipunctatus. 61 54
10369264 1999
19
Recessive mutations in the RLBP1 gene encoding cellular retinaldehyde-binding protein in a form of retinitis punctata albescens. 54 61
10102299 1999
20
Retinitis punctata albescens associated with the Arg135Trp mutation in the rhodopsin gene. 61 54
8554077 1996
21
Optical coherence tomography angiography findings in macular toxoplasma retinochoroiditis: A case report. 61
32551402 2020
22
Identification of a novel homozygous ARSG mutation as the second cause of Usher syndrome type 4. 61
32455177 2020
23
Branch retinal artery occlusion secondary to Bartonella henselae infection in a 13 year-old. 61
32435719 2020
24
Rapid visual field constriction in a patient with retinitis pigmentosa and pituitary adenoma. 61
32566799 2020
25
Identification of a novel homozygous nonsense mutation in the CDHR1 gene in a Chinese family with autosomal recessive retinitis pigmentosa. 61
32277948 2020
26
Beneficial effects of saffron (Crocus sativus L.) in ocular pathologies, particularly neurodegenerative retinal diseases. 61
31997799 2020
27
Expression and purification of the heme exporter FLVCR1a. 61
32278001 2020
28
Identification of novel USH2A mutations in patients with autosomal recessive retinitis pigmentosa via targeted next‑generation sequencing. 61
32319668 2020
29
Atypical Manifestations of Cat-Scratch Disease, United States, 2005-2014. 61
32568056 2020
30
Gene editing prospects for treating inherited retinal diseases. 61
31857428 2020
31
Small-Molecule Ligands that Bind the RET Receptor Activate Neuroprotective Signals Independent of but Modulated by Coreceptor GFRα1. 61
32362584 2020
32
Genetic and clinical findings in a Chinese cohort with Leber congenital amaurosis and early onset severe retinal dystrophy. 61
31630094 2020
33
Effectiveness of dolutegravir-based antiretroviral treatment for HIV-2 infection: retrospective observational study from Western India. 61
32277827 2020
34
A RANDOMIZED PAIRED-EYE TRIAL OF INTRAVITREAL DEXAMETHASONE IMPLANT FOR CYSTOID MACULAR EDEMA IN RETINITIS PIGMENTOSA. 61
31166248 2020
35
Inhibition of acetylcholinesterase attenuated retinal inflammation via suppressing NF-κB activation. 61
32184102 2020
36
Incidence, risk factors, and outcomes of cytomegalovirus retinitis after haploidentical hematopoietic stem cell transplantation. 61
31992849 2020
37
About 3 cases of post-acute retinopathy of chikungunya fever. 61
32505386 2020
38
Neonatal lupus erythematosus presenting with rash, thrombocytopenia compounded by cytomegalovirus colonisation: a diagnostic dilemma. 61
32532904 2020
39
Rickettsia conorii retinitis: an emerging infection in the southeast of the Iberian Peninsula. 61
32553798 2020
40
Qualitative Interviews to Better Understand the Patient Experience and Evaluate Patient-Reported Outcomes (PRO) in RLBP1 Retinitis Pigmentosa (RLBP1 RP). 61
32372289 2020
41
Inner retinal preservation in the photoinducible I307N rhodopsin mutant mouse, a model of autosomal dominant retinitis pigmentosa. 61
31811649 2020
42
Chronic Granulomatous Disease with the McLeod Phenotype: a French National Retrospective Case Series. 61
32562208 2020
43
Select pediatric vitreoretinal disease in the setting of Turner's syndrome. 61
32274445 2020
44
An update on retinal prostheses. 61
31866339 2020
45
Acute retinal necrosis: Clinical manifestation and long-term visual outcomes in a series of polymerase chain reaction-positive patients. 61
32567354 2020
46
Use of augmented reality technology for improving visual acuity of individuals with low vision. 61
32461448 2020
47
Expanding the clinical and phenotypic heterogeneity associated with biallelic variants in ACO2. 61
32519519 2020
48
Pharmacological clearance of misfolded rhodopsin for the treatment of RHO-associated retinitis pigmentosa. 61
32536017 2020
49
Two cases with retinitis pigmentosa that developed severe retinal atrophy long after vitreo-retinal surgery. 61
32420512 2020
50
Cystoid macular edema precipitated by altitude in a patient with X-linked retinitis pigmentosa. 61
32400255 2020

Variations for Retinitis

Expression for Retinitis

Search GEO for disease gene expression data for Retinitis.

Pathways for Retinitis

GO Terms for Retinitis

Cellular components related to Retinitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell projection GO:0042995 9.92 RPGRIP1 RPGR RP2 RP1 RHO PRPH2
2 cilium GO:0005929 9.73 RPGRIP1 RPGR RP2 RP1 FAM161A EYS
3 ciliary basal body GO:0036064 9.67 TOPORS RPGR RP2 FAM161A
4 photoreceptor connecting cilium GO:0032391 9.46 TOPORS RPGRIP1 RP1 FAM161A
5 photoreceptor disc membrane GO:0097381 9.4 RHO PDE6A
6 photoreceptor inner segment GO:0001917 9.35 RP1 RHO PRPH2 FAM161A CERKL
7 photoreceptor outer segment GO:0001750 9.1 RPGR RP1 RHO PRPH2 EYS CERKL

Biological processes related to Retinitis according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 response to stimulus GO:0050896 9.65 RPGRIP1 RPGR RPE65 RP1 RLBP1 RHO
2 retina development in camera-type eye GO:0060041 9.63 RPGRIP1 RPE65 RP1 RHO PRPH2 PDE6A
3 regulation of rhodopsin mediated signaling pathway GO:0022400 9.54 RHO PDE6A
4 detection of light stimulus involved in visual perception GO:0050908 9.52 RPE65 EYS
5 cellular response to light stimulus GO:0071482 9.51 RP1 RHO
6 retinoid metabolic process GO:0001523 9.5 RPE65 RLBP1 RHO
7 retina morphogenesis in camera-type eye GO:0060042 9.49 RPE65 RP1
8 photoreceptor cell outer segment organization GO:0035845 9.48 TOPORS RP1
9 retinal cone cell development GO:0046549 9.46 TOPORS RP1
10 rhodopsin mediated signaling pathway GO:0016056 9.43 RHO PDE6A
11 retinal rod cell development GO:0046548 9.4 TOPORS RP1
12 phototransduction, visible light GO:0007603 9.37 RP1 RHO
13 visual perception GO:0007601 9.36 RPGRIP1 RPGR RPE65 RP2 RP1 RLBP1
14 vitamin A metabolic process GO:0006776 9.26 RPE65 RLBP1

Molecular functions related to Retinitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 11-cis retinal binding GO:0005502 8.62 RLBP1 RHO

Sources for Retinitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....